



November 21, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to enclose a Press Note as regards, the Company having signed a Memorandum of Understanding with the Government of Rajasthan to strengthen healthcare system, reduce prevalence of Cardiovascular Disease and Chronic Obstructive Pulmonary Disease in the Alwar district of Rajasthan.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl: a/a

Lupin Signs MoU with the Government of Rajasthan to strengthen Healthcare system

Collaboration to strengthen healthcare system, reduce prevalence and improve health outcomes for patients diagnosed with Cardiovascular and COPD/Asthma disease in Alwar

Jaipur, November 21, 2022: Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited ('Lupin' BSE: 500257 | NSE: LUPIN | Reuters: LUPIN.BO | Bloomberg: LPCIN) announced today that it has signed a Memorandum of Understanding (MoU) with the Government of Rajasthan to address the prevalence of Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in the Alwar district of Rajasthan.

The MoU was signed in the presence of Dr. K L Meena, Director Public Health, Department of Medical, Health and Family Welfare Government of Rajasthan and Tushara Shankar, Head – Corporate Social Responsibility, Lupin.

As per the MoU, LHWRF will work with the State's Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes. The collaboration will work towards serving the local communities in Alwar through preventive, curative and support-based solutions focused on curing the diseases in the short term and reducing their prevalence in the long term. The program is planned to be rolled out in a phase-wise manner.

Non-communicable diseases (NCDs) contribute to nearly 5.87 million (60%) of all deaths in India. CVD and COPD are two leading causes but the prevalence rate of CVD and deaths due to COPD in Rajasthan both outpace national figures. Rajasthan is also among the most affected states in terms of respiratory disease. These statistics prompted LHWRF to conduct a comprehensive situation analysis of select healthcare facilities approved by the Department of Medical Health Services (DMHS) in the region. The findings of the assessment were then presented to the DMHS for review on September 21, 2022. The department's inputs and suggestions were incorporated in the final project proposal.

The findings of the analysis have helped co-create a program that would systematically address CVD and COPD in the region. Using an evidence-based approach to design support interventions, six key areas have been identified which include educating communities, capacity building, early screening, diagnosis & treatment, establishment of NCD corners at health centers, and a patient health tracking system.

“As a leading healthcare provider in India, Lupin has spearheaded the cause of enhancing access to high quality and affordable medicines and healthcare, including to marginalized and vulnerable populations. As we work with the state government to strengthen existing healthcare systems and programs, our goal is to improve availability, accessibility and utilization of healthcare services.” said **Nilesh Gupta, Managing Director, Lupin.**

The MoU is an initiative of LHWRF's “Lives” program, which aims to improve healthcare access and quality of life for communities.

“We are registering an increase in CVD and COPD cases in Rajasthan. In order to manage these and other NCD diseases, we have signed an MoU with Lupin Foundation. They will work in selected blocks from Alwar district to fill gaps in awareness and health services by developing NCD corners and delivering services through their mobile diagnostic van,” said **Dr. K L Meena, Director Public Health, Department of Medical, Health and Family Welfare Government of Rajasthan.**

“In Alwar, CVD and COPD remain prevalent despite efforts to promote awareness of these NCDs. This collaboration with the State Government will help us improve health outcomes and reduce the burden of these two major diseases. As part of this program, CVD and COPD healthcare will be enhanced in the blocks of Alwar in a phased manner”, said **Tushara Shankar, Head – Corporate Social Responsibility, Lupin.**

About LHWRF

Lupin Human Welfare & Research Foundation (LHWRF) is the social responsibility arm of Lupin limited, which has been working to positively impact rural landscapes since 1988. During its three-decade history, the foundation has touched over 5000 villages in 23 districts across nine states. The organization has been working to address all aspects of development for underprivileged communities in four thematic areas, namely Economic, Social, Infrastructure Development, and Natural Resource Management. It undertakes economic development activities in the fields of agriculture, animal husbandry, women empowerment, and rural industries. The social anchors include health and education, while infrastructure development and natural resource development have been the key drivers of growth in backward regions where it operates. LHWRF has adopted a new strategic approach to working on Lives (Healthcare) and Livelihoods.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com